Work

Oncological outcomes post focal low‐dose‐rate brachytherapy in low‐intermediate risk prostate cancer

Year: 2026

Type: article

Abstract: Objectives: To prospectively evaluate oncological control, pathological progression, and its predictors following focal low-dose-rate (LDR) brachytherapy for low-intermediate risk prostate cancer (PCa). Patients and methods: LIBERATE is a prospective, multi-centre clinical registry of patients who have undergone focal LDR brachytherapy for low-intermediate risk PCa since September 2019 (ACTRN:12619001669189). Unifocal ISUP GG1 (≥10 mm in ≥1 core), GG2 (any length) or GG3 (longest core<10 mm) were included. Follow-up entailed serial PSA measurements, and surveillance mpMRI and repeat transperineal prostate biopsy at 18-24 months post-treatment. Pathological control was achieved on repeat biopsy if there was no cancer or ISUP GG1 in <10 mm of core or GG2-3 grade cancer with radiation treatment effect. Progression was defined as no pathological changes from baseline or tumour upgrading. Results: = 0.001), with a sensitivity of 76.9% and specificity of 90.5%. Conclusion: With a median follow-up of 38 months, these early results suggest that focal LDR brachytherapy for low-intermediate risk, single-lesion, imaging-visible PCa demonstrates satisfactory oncological control. However, further follow-up is needed to assess long-term oncological outcomes.

Source: BJUI Compass

DOI: 10.1002/bco2.70129